These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 24011285)

  • 1. Ulcerated nasal infantile haemangioma treated by oral propranolol.
    Al Dosari S; Riad H
    Dermatol Online J; 2013 May; 19(5):18298. PubMed ID: 24011285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consensus statement for the treatment of infantile haemangiomas with propranolol.
    Smithson SL; Rademaker M; Adams S; Bade S; Bekhor P; Davidson S; Dore A; Drummond C; Fischer G; Gin A; Grills C; Halbert A; Lokmic Z; McCahon E; Morgan VA; Murrell DF; Orchard D; Penington A; Purvis D; Relic J; Robertson S; Robinson AJ; Scardamaglia L; Su J; Tan S; Wargon O; Warren L; Wong LC; Zappala T; Phillips R
    Australas J Dermatol; 2017 May; 58(2):155-159. PubMed ID: 28251611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scoring the therapeutic effects of oral propranolol for infantile hemangioma: A prospective study comparing the Hemangioma Activity Score (HAS) with the Hemangioma Severity Scale (HSS).
    Janmohamed SR; van Oosterhout M; de Laat PC; van Rosmalen J; Madern GC; Oranje AP
    J Am Acad Dermatol; 2015 Aug; 73(2):258-63. PubMed ID: 26183969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful first-line treatment with propranolol of multifocal infantile hepatic hemangioma with high-flow cardiac overload.
    Sciveres M; Marrone G; Pipitone S; Riva S; Spada M; Gridelli B; Maggiore G
    J Pediatr Gastroenterol Nutr; 2011 Dec; 53(6):693-5. PubMed ID: 21519284
    [No Abstract]   [Full Text] [Related]  

  • 5. Tumor lysis syndrome after propranolol therapy in ulcerative infantile hemangioma: rare complication or incidental finding?
    Cavalli R; Buffon RB; de Souza M; Colli AM; Gelmetti C
    Dermatology; 2012; 224(2):106-9. PubMed ID: 22516868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Propranolol for the treatment of infantile haemangioma.
    Dalby TK; Lester-Smith D
    J Paediatr Child Health; 2013 Feb; 49(2):148-51. PubMed ID: 23418706
    [No Abstract]   [Full Text] [Related]  

  • 7. Low-dose propranolol regimen for infantile haemangioma.
    Tan CE; Itinteang T; Leadbitter P; Marsh R; Tan ST
    J Paediatr Child Health; 2015 Apr; 51(4):419-24. PubMed ID: 25187156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infantile hemangioma: treatment with short course systemic corticosteroid therapy as an alternative for propranolol.
    Nieuwenhuis K; de Laat PC; Janmohamed SR; Madern GC; Oranje AP
    Pediatr Dermatol; 2013; 30(1):64-70. PubMed ID: 22958179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new treatment pathway for propranolol use in infantile haemangiomas.
    May JE; Liew SH
    J Plast Reconstr Aesthet Surg; 2014 Mar; 67(3):e91-2. PubMed ID: 24268691
    [No Abstract]   [Full Text] [Related]  

  • 10. Propranolol treatment in life-threatening airway hemangiomas: a case series and review of literature.
    Broeks IJ; Hermans DJ; Dassel AC; van der Vleuten CJ; van Beynum IM
    Int J Pediatr Otorhinolaryngol; 2013 Nov; 77(11):1791-800. PubMed ID: 24074695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety profile during initiation of propranolol for treatment of infantile haemangiomas in an ambulatory day-care hospitalization setting.
    Fogel I; Ollech A; Zvulunov A; Valdman-Greenshpon Y; Atar Snir V; Friedland R; Lapidoth M; Ben-Amitai D
    J Eur Acad Dermatol Venereol; 2018 Nov; 32(11):2004-2009. PubMed ID: 29573481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonsurgical treatment of two cases of infantile facial growths in a resource-poor setting.
    Natawidjaja R; Ewen Wang N
    Wilderness Environ Med; 2015 Mar; 26(1):91-3. PubMed ID: 25712300
    [No Abstract]   [Full Text] [Related]  

  • 13. Preliminary experiences in treating infantile hemangioma with propranolol.
    Chai Q; Chen WL; Huang ZQ; Zhang DM; Fan S; Wang L
    Ann Plast Surg; 2014 Feb; 72(2):169-72. PubMed ID: 21629056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experience with Holter monitoring during propranolol therapy for infantile hemangiomas.
    Jacks SK; Kertesz NJ; Witman PM; Fernandez Faith E
    J Am Acad Dermatol; 2015 Aug; 73(2):255-7. PubMed ID: 26054433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additive effect of propranolol and pulsed dye laser for infantile hemangioma.
    Herschthal J; Wulkan A; George M; Waibel J
    Dermatol Online J; 2013 Jun; 19(6):18570. PubMed ID: 24011319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of infantile capillary hemangioma of the eyelid with systemic propranolol.
    Vassallo P; Forte R; Di Mezza A; Magli A
    Am J Ophthalmol; 2013 Jan; 155(1):165-170.e2. PubMed ID: 22967870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined low-dose oral propranolol and oral prednisolone as first-line treatment in periocular infantile hemangiomas.
    Koay AC; Choo MM; Nathan AM; Omar A; Lim CT
    J Ocul Pharmacol Ther; 2011 Jun; 27(3):309-11. PubMed ID: 21542771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined Oral and Topical Beta Blockers for the Treatment of Early Proliferative Superficial Periocular Infantile Capillary Hemangioma.
    Marey HM; Elmazar HF; Mandour SS; Khairy HA
    J Pediatr Ophthalmol Strabismus; 2018 Jan; 55(1):37-42. PubMed ID: 28991344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Propranolol treatment of infantile hemangiomas does not negatively affect psychomotor development.
    Moyakine AV; Hermans DJ; Fuijkschot J; van der Vleuten CJ
    J Am Acad Dermatol; 2015 Aug; 73(2):341-2. PubMed ID: 26183988
    [No Abstract]   [Full Text] [Related]  

  • 20. Low-dose propranolol for infantile haemangioma.
    Tan ST; Itinteang T; Leadbitter P
    J Plast Reconstr Aesthet Surg; 2011 Mar; 64(3):292-9. PubMed ID: 20615772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.